03 86 03 87 03 U0 03 U0 03 U0 03 03 87 03 03 02	86328 86769 87635 U0003 U0004 U0005	COVID-19 Lab Test Non-CDC  Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19))  Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19))  Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19), amplified probe technique infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19), amplified probe technique making use of high throughput technologies as described by CMS-2020-01-R.  2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R.  Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)), amplified probe technique, CDC or non-CDC, making use of high throughput technologies as described by CMS-2020-01-R.	\$51.33 \$45.23 \$42.13 \$51.31 \$75.00	02/04/2020 04/10/2020 04/10/2020 03/13/2020* 01/01/2021	TBD TBD TBD
03 86 03 87 03 Ut 03 Ut 03 87 03 87 03 02	86328 86769 87635 U0003 U0004 U0005	method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])  Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])  Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.  2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R.  Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19), amplified probe technique, purplied pro	\$42.13 \$51.31 \$75.00	04/10/2020 03/13/2020* 01/01/2021	TBD
03 81 03 Ut 03 Ut 03 81 03 82 03 02	87635 U0003 U0004 U0005	[COVID-19]) Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.  2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R.  Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed withit 2 calendar	\$51.31 \$75.00	03/13/2020*	TBD
03 UI  03 UI  03 UI  03 85  03 85  03 02	U0003 U0004 U0005	coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R. 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R. Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar	\$75.00	01/01/2021	
03 U( 03 U( 03 87 03 87 03 02	U0003 U0004 U0005	coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.  2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R.  Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar	******		TBD
03 UI  03 85  03 85  03 02  03 02	U0004 U0005 87426	subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R.  Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar	\$75.00	01/01/2021	ļ
03 87 03 87 03 02	U0005 87426	coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar		3	TBD
03 87	87426	U0003 or U0004) SARS-CoV-2 CMS-2020-01-R2	\$25.00	01/01/2021	TBD
03 02		Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g. SARS-CoV, SARSCoV-2 [COVID-19])	\$45.23	06/25/2020*	TBD
03 02	87428	Infectious agent antigen detection by immunoassay technique, (eg. enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg. SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B	\$30.94	11/10/2020	TBD
	0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$416.78	06/25/2020*	TBD
03 02		Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed	\$42.13	06/25/2020*	TBD
	0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$416.78	05/20/2020*	TBD
03 86	86408	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen.	\$42.13	8/10/2020	TBD
03 86	86409	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer.	\$105.33	8/10/2020	TBD
03 02	0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.	\$416.78	8/10/2020	TBD
03 02	0226U	Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum.	\$42.28	8/10/2020	TBD
03 86		Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative.	\$42.13	9/8/2020	TBD
03 87	87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	\$142.63	10/6/2020	TBD
03 87	87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	\$142.63	10/6/2020	TBD
03 87	87811	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$41.38	10/6/2020	TBD
03 02	0240U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected	\$142.63	10/6/2020	TBD
03 02	02/111	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSVI), upper respiratory specimen, each pathogen reported as detected or not detected.	\$142.63	10/6/2020	TBD
		40.00.04			

TOS	Procedure Code	Code Description	Fee (effective on/after DOS 01/01/2022)	Effective Date of Service*	End Date of Service
30	U0002	COVID-19 Lab Test Non-CDC	\$51.33	02/04/2020	04/19/2020
30	86328	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$45.23	04/10/2020	TBD
30	86769	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$42.13	04/10/2020	TBD
30	87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique	\$51.31	03/13/2020*	TBD
30	U0003	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.	\$75.00	01/01/2021	TBD
30	U0004	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2/20-01-R.	\$75.00	01/01/2021	TBD
30	U0005	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either HCPCS code U0003 or U0004) SARS-CoV-2 CMS-2020-01-R2	\$25.00	01/01/2021	TBD
30	87426	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g. SARS-CoV, SARSCOV-2 (COVID-19])	\$45.23	06/25/2020*	TBD
30	87428	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELIAS], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B.	\$30.94	11/10/2020	TBD
30	0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$416.78	06/25/2020*	TBD
30	0224U	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed	\$42.13	06/25/2020*	TBD
30	0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$416.78	05/20/2020*	TBD
30	86408	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen.	\$42.13	8/10/2020	TBD
30	86409	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer.	\$105.33	8/10/2020	TBD
30	0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.	\$416.78	8/10/2020	TBD
30	0226U	Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum.	\$42.28	8/10/2020	TBD
30	86413	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative.	\$42.13	9/8/2020	TBD
30	87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	\$142.63	10/6/2020	TBD
30	87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	\$142.63	10/6/2020	TBD
30	87811	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$41.38	10/6/2020	TBD
30	0240U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected	\$142.63	10/6/2020	TBD
30	0241U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected	\$142.63	10/6/2020	TBD
		of service to align with guidance from CMS			

тоѕ	Procedure Code	Code Description	Fee (effective on/after DOS 01/01/2022)	Effective Date of Service*	End Date of Service
37	U0002	COVID-19 Lab Test Non-CDC	\$51.33	02/04/2020	04/19/2020
37	86328	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$45.23	04/10/2020	TBD
37	86769	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$42.13	04/10/2020	TBD
37	87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique	\$51.31	03/13/2020*	TBD
37	U0003	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.	\$75.00	01/01/2021	TBD
37	U0004	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as idescribed by CMS-2020-01-R.	\$75.00	01/01/2021	TBD
37	U0005	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either HCPCS code U0003 or U0004) SARS-CoV-2 CMS-2020-01-R2	\$25.00	01/01/2021	TBD
37	87426	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g. SARS-CoV, SARSCOV-2 [COVID-19])	\$45.23	06/25/2020*	TBD
37	87428	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunoasorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B	\$30.94	11/10/2020	TBD
37	0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$416.78	06/25/2020*	TBD
37	0224U	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed	\$42.13	06/25/2020*	TBD
37	0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$416.78	05/20/2020*	TBD
37	86408	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen.	\$42.13	8/10/2020	TBD
37	86409	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer.	\$105.33	8/10/2020	TBD
37	0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.	\$416.78	8/10/2020	TBD
37	0226U	Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum.	\$42.28	8/10/2020	TBD
37	86413	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative.	\$42.13	9/8/2020	TBD
37	87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	\$142.63	10/6/2020	TBD
37	87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	\$142.63	10/6/2020	TBD
37	87811	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$41.38	10/6/2020	TBD
37	0240U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected	\$142.63	10/6/2020	TBD
37	0241U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus (RSVI), upper respiratory specimen, each pathogen reported as detected or not detected	\$142.63	10/6/2020	TBD

39 863 39 867 39 876 39 U00 39 U00 39 874 39 874 39 022	6328	COVID-19 Lab Test Non-CDC  Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19))  Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19))  Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19))  Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)), amplified probe technique coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)), amplified probe technique infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.  2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R.  Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either HCPCS code U0003 or U0004) SARS-CoV-2 (CMS-2020-01-R2  Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELSA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g. SARS-CoV, SARS-CoV, SARS-CoV, SARS-CoV, SARS-CoV, SARS-CoV, SARS-CoV, SARS-CoV-2 (COVID-19)) and influenza virus types A and B  Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA	\$51.33 \$45.23 \$42.13 \$51.31 \$75.00 \$75.00 \$25.00 \$45.23	02/04/2020 04/10/2020 04/10/2020 03/13/2020* 01/01/2021 01/01/2021 06/25/2020*	TBD TBD TBD TBD TBD TBD TBD TBD
39 867 39 U00 39 U00 39 U00 39 874 39 874 39 022	6328	method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19))  Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19))  Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)), amplified probe technique infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.  2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R.  Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either HCPCS code u0003 or u0004) SARS-CoV-2 CMS-2020-01-R2  Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay (ELISA), immunochemiluminometric assay (IMCA)) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2 COV-2 COV-10-19))  Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay (ELISA), immunochemiluminometric assay (IMCA)) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2) (GOVID-19)) and infuenza virus ypes A and B  Infectious disease (bacterial or viral respiratory tractinection), pathogen-specific indicence acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	\$42.13 \$51.31 \$75.00 \$75.00 \$25.00 \$45.23	04/10/2020  03/13/2020*  01/01/2021  01/01/2021  01/01/2021  11/10/2020*	TBD TBD TBD TBD TBD TBD
39 876 39 U00 39 U00 39 874 39 874 39 022	7635	[COVID-19]) Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-8.  2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R.  Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either HCPCS code U0003 or U0004) SARS-CoV-2 CMS-2020-01-R2.  Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELSA], immunochemiluminometric assay [IMCA]) qualitative or semiquantiative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2 (SARS-CoV-2) (COVID-19]) infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [EIA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantiative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV-2) (Covonavirus 2 (SARS-CoV-2), qualitative or semiquantiative as seen acute respiratory syndrome coronavirus 2 (SARS-C	\$51.31 \$75.00 \$75.00 \$25.00 \$45.23	03/13/2020*  01/01/2021  01/01/2021  01/01/2021  11/10/2020*	TBD  TBD  TBD  TBD
39 U00 39 U00 39 U00 39 874 39 874 39 022	00003   00003   00004   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005   00005	coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.  2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R.  Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either HCPCS code U0003 or U0004) SARS-CoV-2 CMS-2020-01-R2  Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELSA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g. SARS-CoV, SARS-CoV, 2 (COVID-19])  Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [EIA], fluorescence immunoassay [EIA], enzyme-linked immunosorbent assay [EIA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (e.g. SARS-CoV, SARS-CoV, SARS-CoV, SARS-CoV-2) (COVID-19) and influenza virus types A and B  Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative respiratory syndrome coronavirus 2 (SARS-CoV-2), Qualitative coronavirus 2 (SARS-CoV-2) (Covid-2) (Covid-2) (Covid-2) (Covid-	\$75.00 \$75.00 \$25.00 \$45.23	01/01/2021 01/01/2021 01/01/2021 06/25/2020* 11/10/2020	TBD  TBD  TBD  TBD
39 U00 39 U00 39 874 39 874 39 022	00003   1   1   1   1   1   1   1   1   1	coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.  2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R.  Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either HCPCS code U0003 or U0004) SARS-CoV-2 CMS-2020-01-R2 Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [EILSA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV-CVDID-19) infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [EILSA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-CV, SARS-CoV-CV, SARS-CoV-CV) (CVDD-19) and influenza virus yeps A and B infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COV), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$75.00 \$25.00 \$45.23	01/01/2021 01/01/2021 06/25/2020* 11/10/2020	TBD  TBD  TBD
39 U00 39 874 39 874 39 022	0004	subtypes (includes all targets), non-CDC, making use of high throughput technologies as 'described by CMS-2020-01-R.  Inflectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either HCPCS code U0003 or U0004) SARS-CoV-2 CMS-2020-01-R2 Inflectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay (ELIS), immunochemiluminometric assay (IMCA)) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-C) (SARS-CoV-C) (SOVID-19) inflectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay (EIA), intercence immunoassay (FIA), immunochemiluminometric assay (IMCA)) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-C), SARS-CoV-2 (COVID-19) and rifuenza virus ypes A and B inflectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$25.00 \$45.23 \$30.94	01/01/2021 06/25/2020* 11/10/2020	TBD TBD
39 874 39 874 39 022	7426 C	coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either HCPCS code U0003 or U0004) SARS-CoV-2 CMS-2020-01-R2 [Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantiative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV-2 (COVID-19)) infectious agent antigen detection by immunoassay echnique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [LIMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2 (COVID-19)) and rifluenza virus ypes A and B infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 tragets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$45.23 \$30.94	06/25/2020*	TBD
39 874 39 022 39 022	7426 [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [	[EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV, SARSCoV-2 [COVID-19]) infectious agent antigen detection by immunoassay technique, (eg., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [EIIAS], fluorescence immunoassay [FIA], immunochemiluminometric assay [IIMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg., SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid [DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.	\$30.94	11/10/2020	TBD
39 022 39 022	7428 i	enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg. SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus ypes A and B influence of the control of			
39 022	223U (	(DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS- coV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected  Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease	\$416.78	06/25/2020*	TBD
	224U [	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease			
39 020		[COVID-19]), includes titer(s), when performed	\$42.13	06/25/2020*	TBD
	202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS- cOv-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$416.78	05/20/2020*	TBD
39 864	6408	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen.	\$42.13	8/10/2020	TBD
39 864		Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer.	\$105.33	8/10/2020	TBD
39 022	225U 2	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.	\$416.78	8/10/2020	TBD
39 022	226U (	Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum.	\$42.28	8/10/2020	TBD
39 864		Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative.	\$42.13	9/8/2020	TBD
39 876	7636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	\$142.63	10/6/2020	TBD
39 876	7637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	\$142.63	10/6/2020	TBD
39 878	7811	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$41.38	10/6/2020	TBD
39 024	240U a	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected	\$142.63	10/6/2020	TBD
39 024	241U 8	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected	\$142.63	10/6/2020	TBD

тоѕ	Procedure Code	Code Description	Fee (effective on/after DOS 01/01/2022)	Effective Date of Service*	End Date of Service	
40	U0002	COVID-19 Lab Test Non-CDC	\$53.04	02/04/2020	04/19/2020	
40	86328	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$45.23	04/10/2020	TBD	
40	86769	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$42.13	04/10/2020	TBD	
40	87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique	51.31	03/13/2020*	TBD	
40	U0003	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.	\$75.00	01/01/2021	TBD	
40	U0004	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R.	\$75.00	01/01/2021	TBD	
40	U0005	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either HCPCS code U0003 or U0004) SARS-CoV-2 CMS-2020-01-R2	\$25.00	01/01/2021	TBD	
40	87426	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g. SARS-CoV, SARSCOV-2 (COVID-19])	\$46.74	06/25/2020*	TBD	
40	87428	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B	\$30.94	11/10/2020	TBD	
40	0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$430.66	06/25/2020*	TBD	
40	0224U	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed	\$43.53	06/25/2020*	TBD	
40	0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$430.66	05/20/2020*	TBD	
40	86408	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen.	\$43.53	8/10/2020	TBD	
40	86409	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer.	\$108.84	8/10/2020	TBD	
40	0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.	\$430.66	8/10/2020	TBD	
40	0226U	Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum.	\$43.69	8/10/2020	TBD	
40	86413	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative.	\$43.53	9/8/2020	TBD	
40	87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	\$147.38	10/6/2020	TBD	
40	87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	\$147.38	10/6/2020	TBD	
40	87811	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$42.76	10/6/2020	TBD	
40	0240U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], Influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected	\$147.38	10/6/2020	TBD	
40	0241U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected	\$147.38	10/6/2020	TBD	
Revised	effective date	of service to align with guidance from CMS				
TOS (Type	e of Service):	File from which claims are paid.				
	Dhumin's s	usision arread take and independent laborators and independent laborators				
03	Physician, physician-owned labs and independent laboratory services. (Nurse Practitioners, Clinical Nurse Specialists, Certified Nurse Midwives, and Physician Assistants are reimbursed 80% of this fee, e.)					
30	Acute Care Outpatient Hospital					
37	Small Rural (	Outpatient Hospital				
39	State Hospitals Outpatient Hospital					
40	Sole Community Outpatient Hospital					
	1	ı				